TriSalus (TLSI) CEO Mary Szela acquires 3,990 ESPP shares, now holds 1.08M

Rhea-AI Filing Summary

TriSalus Life Sciences CEO Mary T. Szela reported an acquisition of 3,990 shares of common stock. These shares were obtained at $3.87 per share through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this grant, she directly holds 1,077,683 TriSalus shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Szela Mary T

Role CEO and President

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,990	$3.87	$15K

Holdings After Transaction: Common Stock — 1,077,683 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 3,990 shares Acquisition price: $3.87 per share Shares held after: 1,077,683 shares +1 more

4 metrics

Shares acquired 3,990 shares Common stock granted under Employee Stock Purchase Plan

Acquisition price $3.87 per share Price for ESPP acquisition on 2026-06-30

Shares held after 1,077,683 shares Total direct common stock holdings following transaction

Transaction code A Grant, award, or other acquisition of common stock

Key Terms

Employee Stock Purchase Plan, Rule 16b-3, Grant, award, or other acquisition, Common Stock

4 terms

Employee Stock Purchase Plan financial

"Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 16b-3 regulatory

"in a transaction exempt under Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:05 PM Accepted by SEC EDGAR 07/01/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Szela Mary T

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER COLORADO 80031

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		A		3,990(1)	A	$3.87	1,077,683	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

Remarks:

	/s/ Mary Szela	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TLSI CEO Mary T. Szela report?

Mary T. Szela reported acquiring 3,990 TriSalus Life Sciences shares. The shares were obtained through the company’s Employee Stock Purchase Plan as a compensation-related award, not an open-market purchase, and are treated as a routine equity grant.

At what price were the new TLSI shares acquired by the CEO?

The 3,990 shares were acquired at $3.87 per share. This price applies to the Employee Stock Purchase Plan transaction reported and reflects how the plan calculated the purchase cost in this specific period for the CEO.

How many TriSalus (TLSI) shares does the CEO hold after this Form 4?

After the reported transaction, Mary T. Szela directly holds 1,077,683 shares. This figure includes the 3,990 shares acquired through the Employee Stock Purchase Plan and represents her total direct common stock ownership reported in the filing.

Was the TLSI CEO’s share acquisition an open-market buy?

No, the CEO’s acquisition was through the Employee Stock Purchase Plan. The Form 4 describes the transaction as a grant, award, or other acquisition exempt under Rule 16b-3, rather than an open-market purchase on a stock exchange.

What does Rule 16b-3 exemption mean for this TLSI Form 4 transaction?

Rule 16b-3 exemption means the transaction is treated as a director or officer compensation arrangement. The reported 3,990-share acquisition under the Employee Stock Purchase Plan qualifies as an exempt insider transaction rather than a speculative trade in the company’s stock.